Figure 5. At 8 weeks after crush SCI, labelling for BrdU, Foxj1-tdT and GFAP remain qualitatively and quantitatively similar to that seen at 2 weeks after SCI.

(a) Schematic of SCI lesion area shown in (b,c). (b) Single channel and merged immunofluorescence images showing distribution of Foxj1-tdT positive cells and their progeny in relation to the ependymal layer (Ep), lesion core (LC) and GFAP positive astrocytes in the astrocyte scar (AS). (c) Higher magnification view of cells labeled for BrdU, Foxj1-tdT and GFAP in the lesion core, ependyma and astrocyte scar. (d) Schematic of 5 dorso-ventral levels quantified and graphs showing the total number of cells per tissue volume and mean percent of BrdU labeled cells that are co-labeled with GFAP or Foxj1-tdT or both across the entire astrocyte scar, determined from cells counts conducted in an identical manner as at 2 weeks after SCI. n = 3 per group, *p < 0.001 versus GFAP + BrdU only (ANOVA with Newman-Keuls), ^p < 0.001 (t-test).